Ann: Chairman's Address to Shareholders, page-40

Unfortunately the NHP results only relate to safety - nothing to do with efficacy or SVR. I have not seen or heard any statement that confirms that the trial dosing levels produce the same results as the doses in the replicon model and it this this piece of infromation that we need if there is to be no published SVR data. If David confirms that the replicon results are being mirrored in the trial, then that would satisfy my interest.